Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 194-198

  Shih, Chuen Ming ^a   Kuo, Wu Hsien ^b,c   Lin, Chiao Wen ^d   Chen, Wei ^e   Cheng, Wei Erh ^a   Chen, Shuo Chueh ^a   Lee, Yao Ling ^d,f  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Lung cancer; Polymerase chain reaction restriction fragment length polymorphism (PCR RFLP); Single nucleotide polymorphisms (SNPs); Urokinase plasminogen activator (uPA); Urokinase plasminogen activator receptor (uPAR)

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME ACTIVATION; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78650515356     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.004     Document Type: Article

References (48)

1. Shi Z., Stack M.S. Molecules of cell adhesion and extracellular matrix proteolysis in oral squamous cell carcinoma. Histol Histopathol 2010;25:917-932.
2. Xu S., Grande-Allen K.J. The role of cell biology and leaflet remodeling in the progression of heart valve disease. Methodist Debakey Cardiovasc J 2010, 6:2-7.
3. Mekkawy A.H., Morris D.L., Pourgholami M.H. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 2009, 5:1487-1499.
4. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584:1923-1930.
5. Hildenbrand R., Allgayer H., Marx A., Stroebel P. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs 2010;19:641-652.
6. Ho M.L., Chen P.N., Chu S.C., et al. Peonidin 3-glucoside inhibits lung cancer metastasis by downregulation of proteinases activities and MAPK pathway. Nutr Cancer 2010;62:505-516.
7. Altundag O., Altundag K., Morandi P., Gunduz M. Cytokines and chemokines as predictive markers in non-small cell lung cancer patients with brain metastases. Lung Cancer 2005, 47:291-292.
8. Huang Y.T., Heist R.S., Chirieac L.R., et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009, 27:2660-2667.
9. Mostertz W., Stevenson M., Acharya C., et al. Age- and sex-specific genomic profiles in non-small cell lung cancer. Jama 2010;303:535-543.
10. Lee E.B., Jeon H.S., Yoo S.S., et al. Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Ann Surg Oncol 2010;17:2608-2618.
11. Hou J., Aerts J., den Hamer B., et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 2010, 5:e10312.
12. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
13. Arcaroli J., Sankoff J., Liu N., Allison D.B., Maloney J., Abraham E. Association between urokinase haplotypes and outcome from infection-associated acute lung injury. Intensive Care Med 2008, 34:300-307.
14. Chou H.T., Chen Y.T., Wu J.Y., Tsai F.J. Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse. Int J Cardiol 2004, 96:165-170.
15. Begin P., Tremblay K., Daley D., et al. Association of urokinase-type plasminogen activator with asthma and atopy. Am J Respir Crit Care Med 2007, 175:1109-1116.
16. Thornton-Wells T.A., Moore J.H., Martin E.R., Pericak-Vance M.A., Haines J.L. Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Genet Epidemiol 2008, 32:187-203.
17. Stewart C.E., Hall I.P., Parker S.G., et al. PLAUR polymorphisms and lung function in UK smokers. BMC Med Genet 2009, 10:112.
18. Nanbu R., Menoud P.A., Nagamine Y. Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA. Mol Cell Biol 1994, 14:4920-4928.
19. Tran H., Maurer F., Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 2003, 23:7177-7188.
20. Przybylowska K., Szemraj J., Kulig A., Dziki A., Ulanska J., Blasiak J. Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer. Acta Biochim Pol 2008, 55:357-363.
21. Kohonen-Corish M.R., Wang Y., Doe W.F. A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR). Hum Genet 1996, 97:124-125.
22. Wu C.Y., Wu M.S., Chen Y.J., et al. Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer. Hepatogastroenterology 2008, 55:1890-1894.
23. Forsti A., Lei H., Tavelin B., et al. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol 2007, 18:1990-1994.
24. Minisini A.M., Fabbro D., Di Loreto C., et al. Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol 2007, 128:112-117.
25. Hsieh Y.S., Lee Y.L., Yang S.F., et al. Association of EcoRI polymorphism of the metastasis-suppressor gene NME1 with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2007, 58:191-195.
26. Hsu H.S., Lee I.H., Hsu W.H., Kao W.T., Wang Y.C. Polymorphism in the hMSH2 gene (gISV12-6T>C) is a prognostic factor in non-small cell lung cancer. Lung Cancer 2007, 58:123-130.
27. Shih C.M., Lee Y.L., Chiou H.L., et al. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006, 52:15-20.
28. Shih C.M., Lee Y.L., Chiou H.L., et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005, 50:291-297.
29. Tseng R.C., Hsieh F.J., Shih C.M., Hsu H.S., Chen C.Y., Wang Y.C. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer 2009, 115:2939-2948.
30. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999, 5:129-134.
31. Xu J., Li W., Bao X., et al. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond) 2010; 119:353-359.
32. Gosselink J.V., Hayashi S., Elliott W.M., et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:1329-1335.
33. Di Bernardo M.C., Matakidou A., Eisen T., Houlston R.S. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer 2009, 65:237-241.
34. Tsai M.H., Chen W.C., Chen H.Y., Tsai F.J. Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer. J Clin Lab Anal 2004, 18:276-279.
35. Madsen C.D., Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008, 87:617-629.
36. Sidenius N., Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22:205-222.
37. Bentov Y., Brown T.J., Akbari M.R., et al. Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer. PLoS ONE 2009, 4:e5918.
38. Lei H., Hemminki K., Johansson R., et al. PAI-1-675 4 G/5 G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2008, 109:165-175.
39. Yang S.F., Hsieh Y.S., Lin C.L., et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005, 354:91-99.
40. Przybylowska K., Smolarczyk K., Kulig A., et al. Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer. Cancer Lett 2002, 181:23-30.
41. Carriero M.V., Longanesi-Cattani I., Bifulco K., et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009, 8:2708-2717.
42. Weidle U.H., Konig B. Urokinase receptor antagonists: novel agents for the treatment of cancer. Expert Opin Investig Drugs 1998, 7:391-403.
43. Almasi C.E., Hoyer-Hansen G., Christensen I.J., Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009, 117:755-761.
44. Ahmad A., Kong D., Wang Z., Sarkar S.H., Banerjee S., Sarkar F.H. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009, 108:916-925.
45. Thomas C., Wiesner C., Melchior S.W., et al. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int 2009, 104:29-34.
46. Kogianni G., Walker M.M., Waxman J., Sturge J. Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression. Eur J Cancer 2009, 45:685-693.
47. Illemann M., Bird N., Majeed A., et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009, 124:1860-1870.
48. Yang H.C., Lin C.H., Hsu C.L., et al. A comparison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians. J Biomed Sci 2006, 13:489-498.